Novartis’s top-selling medicine is safe from generics — for now
US consumers lose out after judge stops rivals from making cheaper versions of multiple sclerosis drug Gilenya
25 June 2019 - 17:41
Zurich — Novartis has won a US federal court order preventing rival generic makers from selling versions of the Swiss drugmaker’s top-selling multiple sclerosis medicine Gilenya in the US, at least until a patent dispute is resolved.
Novartis had asked for a preliminary injunction to halt generics makers including Dr Reddy’s Laboratories, Mylan Pharmaceuticals, Torrent Pharma and Aurobindo Pharma, among others, from making or selling a Gilenya copy in the US until a final decision on a Novartis patent for the medicine...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.